CCEL logo

CRYO-CELL INTL INC

CCELNYSE AMERICAN
πŸ† #4617 by market capEarnings Oct 9US Equity
$4.10β–Ό $0.06 (βˆ’1.44%)
πŸŒ™ After hours$4.16β–² 1.46%Regular close Β· extended-hours price shown
πŸ””
Track CCEL
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.4%
7dβ–Ό 2.3%
14dβ–Ό 7.2%
30dβ–Ό 4.7%
ytdβ–² 18.8%
1yβ–Ό 16.7%
🏦Market Cap
$33M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-1.3%
Declining
πŸ“ŠGross Margin
77.3%
High
πŸ’΅FCF Margin
19.6%
Healthy
βš–οΈP/S Ratio
1.1x
Cheap
Otter Score
72
Fair

Trading Snapshot

Day Range
$4.08 – $4.17
52-Week Range
$2.72 – $4.90
Volume
$2.40B
Avg Volume
$3.12B
Shares Outstanding
8.1M
Next Earnings
Dec 11, 2026

Fundamentals Snapshot

Annual Revenue
$32M
Last Q Revenue
$8M
P/E Ratio
-13.9
P/S Ratio
1.1x
EPS (TTM)
$-0.31
Dividend Yield
0.00%
Dilution (1yr)
βˆ’1.8%

Why Investors Own CCEL

  • βœ“High-growth profile β€” revenue up +35.2% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 72% gross margin and 10% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CCEL logo

CRYO-CELL INTL INC

CCEL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$32Mβ–Ό βˆ’1.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
76.6%β–² +2.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$5Mβ–² +39.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$5Mβ–² +118.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
8.1Mβ–Ό βˆ’1.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$11Mβ–² +$1M YoY
StockOtter Β· stockotter.space

About CRYO-CELL INTL INC

Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
72/100

Analyst Ratings

β“˜
Consensus
Sell
6 analysts
Strong Buy0
Buy0
Hold3
Sell1
Strong Sell2
Ratings as of Sep 2026

Latest News & Updates